Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
Discontinued
Reference number: GID-TA10271
Following on from information provided to NICE by the company in November 2018, the appraisal of Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.